About CRISPER / Cas9 patent dispute

I spoke as a speaker at Clubhouse (American Intellectual Property and Legal on Clubhouse) about the CRISPER / Cas9 patent dispute this afternoon.

* Here is the clubhouse room I talked about:
American Intellectual Property and Legal on Clubhouse

* I talk in Clubhouse occasionally, so please check from my office website and Twitter of Mr. Noguchi, a US lawyer who is the organizer for details:

Etoile International IP Law Firm
Noguchi’s Twitter

CRISPER / Cas9 is one of the genome editing technologies, and this groundbreaking technology is currently being used in all fields related to biotechnology.

On the other hand, regarding the patent related to CRISPER / Cas9, the University of California, to which the Nobel Prize-winning researchers belong, and the Broad Institute (Harbord University and Massachusetts Institute of Technology), which are said to have been the first to succeed in an application to mammalian cells. There is a fierce dispute between them, and patent disputes are ongoing with other organizations on related technologies. I talked about the fact that one of the conclusions of the US patent dispute that had been disputed was reached, and this time, in the US patent dispute, the Broad Institute won.

As mentioned above, CRISPER / Cas9 technology is widely used in medical applications and agricultural fields, and the problem with such patent disputes is that for companies that want to use it for commercial purposes, they cannot find which patents they should get licensed. It is also necessary to keep an eye on the progress of the patent dispute, which may hinder the development of the industry in the end, because the rights are unstable while the patent dispute continues. It seems that patent pools are being tried, but unlike other fields, especially in the medical field, it has taken the form of firmly protecting the core technology with a small number of patents, and this time about this epoch-making technology, I would like to keep an eye on the consequences of what kind of solutions will be taken from the perspective of patents.

Reference article:

UC Berkeley loses CRISPR patent case – The Verge

CRISPR / Cas9 Basic Patent Conflict (University of California vs Broad Institute) Settled at US Patent and Trademark Office | Biostation

( 3) Genome editing technology CRISPR / Cas9-From the aspect of patents and licenses-

* This photo is a cafe about four and a half years ago. Most of the photos I’ve posted so far are a thing of the past. Little by little, I was able to visit a cafe again. I just hope that this year will be the last year of Covid-19.